Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cancer vaccine MUC-1 - Immutep Limited

X
Drug Profile

Cancer vaccine MUC-1 - Immutep Limited

Alternative Names: CVac; M-FP cancer vaccine; Mannan-MUC1 fusion protein; MUC1 dendritic cell vaccine

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Prima Biomed
  • Developer Immutep Limited; Prima BioMed
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action Immunostimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Registered Ovarian cancer
  • Discontinued Pancreatic cancer

Most Recent Events

  • 28 Nov 2017 Prima BioMed is now called Immutep Limited
  • 19 May 2015 Updated efficacy results from a phase II trial in Ovarian cancer released by Prima BioMed
  • 01 Apr 2015 Prima BioMed completes a phase II trial for Ovarian cancer in USA and Australia (NCT01068509)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top